Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies

Conclusion: 64Cu-NOTA-trastuzumab was effectively targeted to the HER2-expressing tumor in vitro and in vivo, and it exhibited a relatively low absorbed dose due to a short residence time. Therefore, 64Cu-NOTA-trastuzumab could be applied to select the right patients and right timing for HER2 therapy, to monitor the treatment response after HER2-targeted therapy, and to detect distal or metastatic spread.

Source: Journal of Nuclear Medicine - January 2, 2019 Category: Nuclear Medicine Authors: Woo, S.-K., Jang, S. J., Seo, M.-J., Park, J. H., Kim, B. S., Kim, E. J., Lee, Y. J., Lee, T. S., An, G. I., Song, I. H., Seo, Y., Kim, K. I., Kang, J. H. Tags: Translational Source Type: research